Drug intelligence / Profile preview

Limosilactobacillus fermentum UP-1

Development stage: Preclinical
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral, Topical, Intranasal, Inhalation

Overview

Limosilactobacillus fermentum UP-1 is a specific strain of the species Limosilactobacillus fermentum, a Gram-positive, heterofermentative lactic acid bacterium. The species is naturally found in the human body and in various fermented foods. Certain strains of L. fermentum are used as probiotics due to their potential to support gut health by helping break down food, absorb nutrients, and inhibit pathogenic organisms. While several strains (such as PCC, ME-3, and CECT5716) have been commercialized for probiotic use or studied for benefits like reducing gastrointestinal infections or supporting immune function[2][4], there is no direct evidence regarding the unique properties or clinical applications of the UP-1 strain specifically in publicly available literature as of June 2025.

Other names: Lactobacillus fermentum UP-1

Targets

Shigella spp. (Shigella species)

Beyond the preview

Go deeper on Limosilactobacillus fermentum UP-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Limosilactobacillus fermentum UP-1.

Explore the full profile